Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threat ...

ELKHART, Ind., Oct. 30, 2024 /PRNewswire/ -- Hurricane Boats, legendary innovator in versatile deck boat designs, ushers in the next chapter in its storied history with the launch of its latest model for 2025 – the SunDeck 3200. A stunning extension of their current yacht series line-up which includes the 2600 and 2690, the SunDeck 3200 is the latest high point of Hurricane Boats' designs. Hurricane Boats, legendary innovator in versatile deck boat designs, ushers in the next chapter in its storied history ...

Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $15.01, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $36.13 indicates a 140.7% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $6.33. While the lowest estimate of $24 indicates a 59.9% increase from the current price level, the most opt ...

BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024. Live audio of the webcast will be accessible ...

When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top. After setting a new record high last month, the S&P 500 has peeled back 5% from that level. A string of upcoming economic indicators coming out this week could determine whether the economy is heading into a recession or if the Federal Reserve will cut interest rates. Stocks are flailing to and fro as investors try to gauge the direction. Yet analysts at Bank of America ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. Day One Biopharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.19 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 810.22%. This compares to zero revenues a year ago. W ...

Exhibit 99.1 Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million Company to host conference call and webcast today, July 30, 8:00 a.m. Eastern Time BRISBANE, Calif., Jul. 30, 2024 – Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today ann ...

Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 About Day One Biopharmaceuticals Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by "The Day ...

Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threaten ...